Agency Information Collection Activities: Submission for OMB Review; Comment Request, 40077-40079 [2019-17282]

Download as PDF 40077 Federal Register / Vol. 84, No. 156 / Tuesday, August 13, 2019 / Notices ESTIMATED ANNUAL REPORTING REQUIREMENT BURDEN FOR OPIOID TREATMENT PROGRAMS—Continued Purpose 8.11(e)(1) ............ 8.11(e)(2) ............ Application for provisional certification Application for extension of provisional certification. Notification of sponsor or medical director change (SMA–162). Documentation to SAMHSA for interim maintenance. Request to SAMHSA for Exemption from 8.11 and 8.12 (including SMA–168). Notification to SAMHSA Before Establishing Medication Units (SMA–162). Notification to State Health Officer When Patient Begins Interim Maintenance. Contents of Appellant Request for Review of Suspension. Informal Review Request .................... Appellant’s Review File and Written Statement. Appellant’s Request for Expedited Review. Appellant Review File and Written Statement. 8.11(f)(5) ............. 8.11(g)(2) ............ 8.11(h) ................ 8.11(i)(1) ............. 8.12(j)(2) ............. 8.24 ..................... 8.25(a) ................ 8.26(a) ................ 8.28(a) ................ 8.28(c) ................ Responses/ respondent Total responses Hours/ response Total hours 42 30 1 1 42 30 1 0.25 42.00 7.50 60 1 60 0.1 6.00 1 1 1 1 1.00 1,200 20 24,000 0.07 1,680 10 1 10 0.25 2.5 1 20 20 0.33 6.6 2 1 2 0.25 .50 2 2 1 1 2 2 1.00 5.00 2.00 10.00 2 1 2 1.00 2.00 2 1 2 5.00 10.00 Subtotal ....... ............................................................. 1,775 ........................ 24,594 ........................ 1,868.95 Total ..... ............................................................. 1,829 ........................ 26,001 ........................ 2,263.15 Written comments and recommendations concerning the proposed information collection should be sent by September 12, 2019 to the SAMHSA Desk Officer at the Office of Information and Regulatory Affairs, Office of Management and Budget (OMB). To ensure timely receipt of comments, and to avoid potential delays in OMB’s receipt and processing of mail sent through the U.S. Postal Service, commenters are encouraged to submit their comments to OMB via email to: OIRA_Submission@omb.eop.gov. Although commenters are encouraged to send their comments via email, commenters may also fax their comments to: 202–395–7285. Commenters may also mail them to: Office of Management and Budget, Office of Information and Regulatory Affairs, New Executive Office Building, Room 10102, Washington, DC 20503. DEPARTMENT OF HEALTH AND HUMAN SERVICES establish policy, direct program activities, and better allocate resources. Substance Abuse and Mental Health Services Administration 2020 NSDUH Main Study Summer King, Statistician. The National Survey on Drug Use and Health (NSDUH) is a survey of the U.S. civilian, non-institutionalized population aged 12 years old or older. The data are used to determine the prevalence of use of tobacco products, alcohol, illicit substances, and illicit use of prescription drugs. The results are used by SAMHSA, the Office of National Drug Control Policy (ONDCP), federal government agencies, and other organizations and researchers to [FR Doc. 2019–17261 Filed 8–12–19; 8:45 am] BILLING CODE 4162–20–P jspears on DSK3GMQ082PROD with NOTICES Number of respondents 42 CFR citation VerDate Sep<11>2014 17:51 Aug 12, 2019 Jkt 247001 Agency Information Collection Activities: Submission for OMB Review; Comment Request Periodically, the Substance Abuse and Mental Health Services Administration (SAMHSA) will publish a summary of information collection requests under OMB review, in compliance with the Paperwork Reduction Act (44 U.S.C. Chapter 35). To request a copy of these documents, call the SAMHSA Reports Clearance Officer on (240) 276–1112. Project: 2020 National Survey on Drug Use and Health, Clinical Validation Study and Redesign Field Test (OMB No. 0930–0110)—Revision to 2019 NSDUH Collection PO 00000 Frm 00058 Fmt 4703 Sfmt 4703 NSDUH must be updated periodically to reflect changing substance use and mental health issues and to continue producing current data. For the 2020 NSDUH main study the following changes from 2019 are planned: (1) The addition of lifetime and recency questions about vaping anything and vaping nicotine or tobacco; the addition of lifetime and recency questions on synthetic marijuana and synthetic stimulants; (2) the addition of questions in concordance with the Diagnostic and Statistical Manual of Mental Disorders (DSM), fifth edition criteria (DSM–5) to measure the occurrence of marijuana withdrawal symptoms, occurrence of prescription tranquilizer misuse withdrawal symptoms and occurrence of craving for all substances; (3) minor revisions to the marijuana marketplace module; and (4) other minor wording changes to improve the flow of the interview, increase respondent comprehension or to be consistent with text in other questions. By including these new questions in NSDUH, estimates may be generated on the use of these substances among the general population and allow SAMHSA to provide national-level estimates among adults and adolescents on the E:\FR\FM\13AUN1.SGM 13AUN1 40078 Federal Register / Vol. 84, No. 156 / Tuesday, August 13, 2019 / Notices use of vaping, synthetic marijuana, and synthetic stimulants. In addition, because NSDUH collects demographic, socioeconomic, and health information about each respondent, the inclusion of these questions would permit a more detailed understanding of factors associated with their use. The new questions on craving for all substances and withdrawal for marijuana/cannabis were added to the 2020 NSDUH main study to reflect the updated DSM–5 diagnostic criteria for substance use disorders. Questions measuring withdrawal for tranquilizers have been added to ensure SUD for tranquilizers is accurately assessed as well. The marijuana marketplace module (originally dropped in the 2015 redesign questionnaire) was reinserted in the NSDUH main study questionnaire starting in 2018 at the request of ONDCP but was unchanged from the version previously used in the 2014 NSDUH. (This module was not part of the NSDUH questionnaire from 2015–2017.) This module consists of a series of questions that seek to gather data such as the location, quantity, cost and type of marijuana being purchased across the nation. Revisions have been made to this module for 2020 to reflect the availability that marijuana can now be purchased from a retail store or dispensary. As with all NSDUH/NHSDA surveys conducted since 1999, the sample size of the NSDUH main study for 2020 will be sufficient to permit prevalence estimates for each of the fifty states and the District of Columbia. (Prior to 2002, the NSDUH was referred to as the National Household Survey on Drug Abuse (NHSDA). The total annual burden estimate for the NSDUH main study is shown below in Table 1. TABLE 1—ANNUALIZED ESTIMATED BURDEN FOR 2020 NSDUH Number of respondents Instrument Responses per respondent Total number of responses Hours per response Total burden hours Household Screening ........................................................... Interview ............................................................................... Screening Verification .......................................................... Interview Verification ............................................................ 143,255 69,007 4,348 10,351 1 1 1 1 143,255 69,007 4,348 10,351 0.083 1.000 0.067 0.067 11,890 69,007 291 694 Total .............................................................................. 143,255 ........................ 226,961 ........................ 81,882 Clinical Validation Study In addition, a Clinical Validation Study (CVS) is planned to be embedded within the first six months of 2020 NSDUH main study data collection to assess revisions to the substance use disorders (SUD) module to be consistent with the DSM–5. The CVS will examine the validity of this revised NSDUH assessment of SUD by administering questions to adults and adolescents who will then be interviewed by clinical interviewers (who are blinded to the NSDUH main study responses) and classified as having or not having substance use disorders based on past year DSM–5 disorders, as assessed by the Structured Clinical Interview for DSM–5 (SCID–5) During CVS data collection from January through June 2020, approximately 1,500 NSDUH main study interview respondents will be selected for a follow-up clinical interview at the end of the main study interview in order to produce a final sample size of approximately 826 CVS respondents. These follow-up clinical interviews will be conducted via telephone using the SCID–5 within two to four weeks following the NSDUH main study interview. Many of the procedures and protocols planned for inclusion in this CVS are based upon those previously employed as part of the 2018 National Mental Health Study (approved under OMB No. 0930–0380) and the 2008–2012 NSDUH Mental Health Surveillance Study (approved as an add-on to NSDUH under OMB No. 0930–0110). Also, to complete training prior to CVS data collection, each clinical interviewer candidate hired must successfully administer the follow-up clinical interview with a volunteer respondent. These 70 certification interviews will be administered in the same manner as CVS follow-up clinical interviews. The total annual burden estimate for the CVS is shown below in Table 2. TABLE 2—ANNUALIZED ESTIMATED BURDEN FOR 2020 NSDUH CVS Number of respondents Instrument Total number of responses Hours per response Total burden hours Follow-Up Clinical Interviews ............................................... Follow-Up Clinical Certifications .......................................... 800 70 1 1 800 70 0.83 0.83 664 58 Total .............................................................................. 870 ........................ 870 ........................ 722 Redesign Field Test jspears on DSK3GMQ082PROD with NOTICES Responses per respondent Also, as part of SAMHSA’s ongoing effort to ensure NSDUH continues producing current and accurate data, a Redesign Field Test (FT) is planned from August through November 2020 to assess potential revisions to the NSDUH main study questionnaire. These VerDate Sep<11>2014 17:51 Aug 12, 2019 Jkt 247001 revisions are designed to address changing policy and research data needs; in addition, modifications to associated survey materials and methods are designed to improve the quality of estimates and the efficiency of data collection. Planned FT modifications include changes to respondent incentives, respondent PO 00000 Frm 00059 Fmt 4703 Sfmt 4703 materials, the household screening questionnaire, the interview questionnaire, and other data collection methods. The FT is essential for providing a thorough examination of these planned changes prior to their deployment on the NSDUH main study to determine potential impact across operational and E:\FR\FM\13AUN1.SGM 13AUN1 40079 Federal Register / Vol. 84, No. 156 / Tuesday, August 13, 2019 / Notices substantive domains, including effects on data quality (as measured by outcomes such as unit nonresponse, item nonresponse, and survey responses), questionnaire timing, data collection efficiency, and possible differences in reporting of substance use or mental health items. During FT data collection from August through November 2020, conducted separately from ongoing 2020 NSDUH main study data collection at that time, screenings will be completed with approximately 8,110 Englishspeaking respondents in the contiguous United States. (Alaska and Hawaii are excluded from the FT to control study costs.) From those screenings, approximately 4,000 respondents, as representatives of the civilian, noninstitutional population aged 12 years old or older, are expected to complete a FT interview using the revised questionnaire and materials. For the NSDUH FT screening, revisions may include: (1) A revised roster structure; (2) various wording edits to improve respondent comprehension and flow; (3) the use of revised materials, such as the lead letter, study description and question & answer brochure; (4) a conditional test of a $5 screening incentive to assess impact on response rates; and (5) the inclusion of two outcome questions on past month alcohol and past month cigarette use at the end of the screening to assess nonresponse bias from the screening incentive. For the NSDUH FT interview, revisions may include: (1) A conditional test of a $50 interview incentive to assess impact on response rates; (2) revisions to the DSM–5-based SUD module as a result of prior testing in the CVS; (3) the inclusion of new modules on substance use treatment and mental health service utilization; (4) the addition of new and/or revised questions on a variety of items such as Electronic Nicotine Delivery Systems (ENDS), synthetic drugs, pain and sleep, vaping and needle use, and criminal justice; (5) the addition of measures of adolescent psychological distress and/or impairment; (6) the expansion of suicide items; and (7) other general questionnaire revisions such as clarifying wording and terminology, reordering for improved question flow, formatting changes, removal of questions with low prevalence rates, and other minor updates and revisions. The total annual burden estimate for the FT is shown below in Table 3. TABLE 3—ANNUALIZED ESTIMATED BURDEN FOR REDESIGN FIELD TEST Number of respondents Instrument Total number of responses Hours per response Total burden hours Household Screening ........................................................... Interview ............................................................................... Screening Verification .......................................................... Interview Verification ............................................................ 8,110 4,000 246 600 1 1 1 1 8,110 4,000 246 600 0.083 1.000 0.067 0.067 673 4,000 17 40 Total .............................................................................. 8,110 ........................ 12,596 ........................ 4,730 Written comments and recommendations concerning the proposed information collection should be sent by September 12, 2019 to the SAMHSA Desk Officer at the Office of Information and Regulatory Affairs, Office of Management and Budget (OMB). To ensure timely receipt of comments, and to avoid potential delays in OMB’s receipt and processing of mail sent through the U.S. Postal Service, commenters are encouraged to submit their comments to OMB via email to: OIRA_Submission@omb.eop.gov. Although commenters are encouraged to send their comments via email, commenters may also fax their comments to: 202–395–7285. Commenters may also mail them to: Office of Management and Budget, Office of Information and Regulatory Affairs, New Executive Office Building, Room 10102, Washington, DC 20503. jspears on DSK3GMQ082PROD with NOTICES Responses per respondent Summer King, Statistician. [FR Doc. 2019–17282 Filed 8–12–19; 8:45 am] BILLING CODE 4162–20–P VerDate Sep<11>2014 17:51 Aug 12, 2019 Jkt 247001 DEPARTMENT OF HOMELAND SECURITY U.S. Customs and Border Protection Test Concerning Entry of Section 321 Low-Valued Shipments Through Automated Commercial Environment (ACE) U.S. Customs and Border Protection, Department of Homeland Security. ACTION: General notice. AGENCY: SUMMARY: This document announces that U.S. Customs and Border Protection (CBP) is conducting a test of new functionalities related to the electronic entry filing for low-valued shipments through the Automated Commercial Environment (ACE). The Section 321 de minimis administrative exemption admits free from duty and tax, shipments of merchandise (other than bona-fide gifts and certain personal and household goods) imported by one person on one day having an aggregate fair retail value in the country of shipment of not more than $800. During this test, an owner, or purchaser of a Section 321 low-valued shipment or, when appropriately designated, a customs broker appointed by an owner, PO 00000 Frm 00060 Fmt 4703 Sfmt 4703 purchaser, or consignee, will be able to file a new type of informal entry in ACE for Section 321 low-valued shipments. Section 321 low-valued shipments subject to Partner Government Agency (PGA) requirements will also be able to be entered using this new Section 321 informal entry type. This notice provides a description of the test, the requirements for filing the new informal entry type, and the regulations that will be waived for test participants. CBP invites public comment concerning the test program. The test will be known as the ACE Entry Type 86 Test. DATES: The test will commence no earlier than September 28, 2019 and will continue until concluded by an announcement published in the Federal Register. Comments will be accepted throughout the duration of the test. ADDRESSES: Comments concerning this notice and any aspect of this test may be submitted at any time during the test via email to OTENTRYSUMMARY@ cbp.dhs.gov. In the subject line of your email, please indicate, ‘‘Comment on the ACE Entry Type 86 Test.’’ FOR FURTHER INFORMATION CONTACT: Randy Mitchell, Director, Commercial Operations, Revenue and Entry Division, Office of Trade, U.S. Customs E:\FR\FM\13AUN1.SGM 13AUN1

Agencies

[Federal Register Volume 84, Number 156 (Tuesday, August 13, 2019)]
[Notices]
[Pages 40077-40079]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2019-17282]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Substance Abuse and Mental Health Services Administration


Agency Information Collection Activities: Submission for OMB 
Review; Comment Request

    Periodically, the Substance Abuse and Mental Health Services 
Administration (SAMHSA) will publish a summary of information 
collection requests under OMB review, in compliance with the Paperwork 
Reduction Act (44 U.S.C. Chapter 35). To request a copy of these 
documents, call the SAMHSA Reports Clearance Officer on (240) 276-1112.

Project: 2020 National Survey on Drug Use and Health, Clinical 
Validation Study and Redesign Field Test (OMB No. 0930-0110)--Revision 
to 2019 NSDUH Collection

    The National Survey on Drug Use and Health (NSDUH) is a survey of 
the U.S. civilian, non-institutionalized population aged 12 years old 
or older. The data are used to determine the prevalence of use of 
tobacco products, alcohol, illicit substances, and illicit use of 
prescription drugs. The results are used by SAMHSA, the Office of 
National Drug Control Policy (ONDCP), federal government agencies, and 
other organizations and researchers to establish policy, direct program 
activities, and better allocate resources.

2020 NSDUH Main Study

    NSDUH must be updated periodically to reflect changing substance 
use and mental health issues and to continue producing current data. 
For the 2020 NSDUH main study the following changes from 2019 are 
planned: (1) The addition of lifetime and recency questions about 
vaping anything and vaping nicotine or tobacco; the addition of 
lifetime and recency questions on synthetic marijuana and synthetic 
stimulants; (2) the addition of questions in concordance with the 
Diagnostic and Statistical Manual of Mental Disorders (DSM), fifth 
edition criteria (DSM-5) to measure the occurrence of marijuana 
withdrawal symptoms, occurrence of prescription tranquilizer misuse 
withdrawal symptoms and occurrence of craving for all substances; (3) 
minor revisions to the marijuana marketplace module; and (4) other 
minor wording changes to improve the flow of the interview, increase 
respondent comprehension or to be consistent with text in other 
questions.
    By including these new questions in NSDUH, estimates may be 
generated on the use of these substances among the general population 
and allow SAMHSA to provide national-level estimates among adults and 
adolescents on the

[[Page 40078]]

use of vaping, synthetic marijuana, and synthetic stimulants. In 
addition, because NSDUH collects demographic, socioeconomic, and health 
information about each respondent, the inclusion of these questions 
would permit a more detailed understanding of factors associated with 
their use.
    The new questions on craving for all substances and withdrawal for 
marijuana/cannabis were added to the 2020 NSDUH main study to reflect 
the updated DSM-5 diagnostic criteria for substance use disorders. 
Questions measuring withdrawal for tranquilizers have been added to 
ensure SUD for tranquilizers is accurately assessed as well.
    The marijuana marketplace module (originally dropped in the 2015 
redesign questionnaire) was reinserted in the NSDUH main study 
questionnaire starting in 2018 at the request of ONDCP but was 
unchanged from the version previously used in the 2014 NSDUH. (This 
module was not part of the NSDUH questionnaire from 2015-2017.) This 
module consists of a series of questions that seek to gather data such 
as the location, quantity, cost and type of marijuana being purchased 
across the nation. Revisions have been made to this module for 2020 to 
reflect the availability that marijuana can now be purchased from a 
retail store or dispensary.
    As with all NSDUH/NHSDA surveys conducted since 1999, the sample 
size of the NSDUH main study for 2020 will be sufficient to permit 
prevalence estimates for each of the fifty states and the District of 
Columbia. (Prior to 2002, the NSDUH was referred to as the National 
Household Survey on Drug Abuse (NHSDA). The total annual burden 
estimate for the NSDUH main study is shown below in Table 1.

                               Table 1--Annualized Estimated Burden for 2020 NSDUH
----------------------------------------------------------------------------------------------------------------
                                     Number of     Responses per   Total number      Hours per     Total burden
           Instrument               respondents     respondent     of responses      response          hours
----------------------------------------------------------------------------------------------------------------
Household Screening.............         143,255               1         143,255           0.083          11,890
Interview.......................          69,007               1          69,007           1.000          69,007
Screening Verification..........           4,348               1           4,348           0.067             291
Interview Verification..........          10,351               1          10,351           0.067             694
                                 -------------------------------------------------------------------------------
    Total.......................         143,255  ..............         226,961  ..............          81,882
----------------------------------------------------------------------------------------------------------------

Clinical Validation Study

    In addition, a Clinical Validation Study (CVS) is planned to be 
embedded within the first six months of 2020 NSDUH main study data 
collection to assess revisions to the substance use disorders (SUD) 
module to be consistent with the DSM-5. The CVS will examine the 
validity of this revised NSDUH assessment of SUD by administering 
questions to adults and adolescents who will then be interviewed by 
clinical interviewers (who are blinded to the NSDUH main study 
responses) and classified as having or not having substance use 
disorders based on past year DSM-5 disorders, as assessed by the 
Structured Clinical Interview for DSM-5 (SCID-5)
    During CVS data collection from January through June 2020, 
approximately 1,500 NSDUH main study interview respondents will be 
selected for a follow-up clinical interview at the end of the main 
study interview in order to produce a final sample size of 
approximately 826 CVS respondents. These follow-up clinical interviews 
will be conducted via telephone using the SCID-5 within two to four 
weeks following the NSDUH main study interview.
    Many of the procedures and protocols planned for inclusion in this 
CVS are based upon those previously employed as part of the 2018 
National Mental Health Study (approved under OMB No. 0930-0380) and the 
2008-2012 NSDUH Mental Health Surveillance Study (approved as an add-on 
to NSDUH under OMB No. 0930-0110).
    Also, to complete training prior to CVS data collection, each 
clinical interviewer candidate hired must successfully administer the 
follow-up clinical interview with a volunteer respondent. These 70 
certification interviews will be administered in the same manner as CVS 
follow-up clinical interviews.
    The total annual burden estimate for the CVS is shown below in 
Table 2.

                             Table 2--Annualized Estimated Burden for 2020 NSDUH CVS
----------------------------------------------------------------------------------------------------------------
                                     Number of     Responses per   Total number      Hours per     Total burden
           Instrument               respondents     respondent     of responses      response          hours
----------------------------------------------------------------------------------------------------------------
Follow-Up Clinical Interviews...             800               1             800            0.83             664
Follow-Up Clinical                            70               1              70            0.83              58
 Certifications.................
                                 -------------------------------------------------------------------------------
    Total.......................             870  ..............             870  ..............             722
----------------------------------------------------------------------------------------------------------------

Redesign Field Test

    Also, as part of SAMHSA's ongoing effort to ensure NSDUH continues 
producing current and accurate data, a Redesign Field Test (FT) is 
planned from August through November 2020 to assess potential revisions 
to the NSDUH main study questionnaire. These revisions are designed to 
address changing policy and research data needs; in addition, 
modifications to associated survey materials and methods are designed 
to improve the quality of estimates and the efficiency of data 
collection. Planned FT modifications include changes to respondent 
incentives, respondent materials, the household screening 
questionnaire, the interview questionnaire, and other data collection 
methods.
    The FT is essential for providing a thorough examination of these 
planned changes prior to their deployment on the NSDUH main study to 
determine potential impact across operational and

[[Page 40079]]

substantive domains, including effects on data quality (as measured by 
outcomes such as unit nonresponse, item nonresponse, and survey 
responses), questionnaire timing, data collection efficiency, and 
possible differences in reporting of substance use or mental health 
items.
    During FT data collection from August through November 2020, 
conducted separately from ongoing 2020 NSDUH main study data collection 
at that time, screenings will be completed with approximately 8,110 
English-speaking respondents in the contiguous United States. (Alaska 
and Hawaii are excluded from the FT to control study costs.) From those 
screenings, approximately 4,000 respondents, as representatives of the 
civilian, noninstitutional population aged 12 years old or older, are 
expected to complete a FT interview using the revised questionnaire and 
materials.
    For the NSDUH FT screening, revisions may include: (1) A revised 
roster structure; (2) various wording edits to improve respondent 
comprehension and flow; (3) the use of revised materials, such as the 
lead letter, study description and question & answer brochure; (4) a 
conditional test of a $5 screening incentive to assess impact on 
response rates; and (5) the inclusion of two outcome questions on past 
month alcohol and past month cigarette use at the end of the screening 
to assess nonresponse bias from the screening incentive.
    For the NSDUH FT interview, revisions may include: (1) A 
conditional test of a $50 interview incentive to assess impact on 
response rates; (2) revisions to the DSM-5-based SUD module as a result 
of prior testing in the CVS; (3) the inclusion of new modules on 
substance use treatment and mental health service utilization; (4) the 
addition of new and/or revised questions on a variety of items such as 
Electronic Nicotine Delivery Systems (ENDS), synthetic drugs, pain and 
sleep, vaping and needle use, and criminal justice; (5) the addition of 
measures of adolescent psychological distress and/or impairment; (6) 
the expansion of suicide items; and (7) other general questionnaire 
revisions such as clarifying wording and terminology, reordering for 
improved question flow, formatting changes, removal of questions with 
low prevalence rates, and other minor updates and revisions.
    The total annual burden estimate for the FT is shown below in Table 
3.

                          Table 3--Annualized Estimated Burden for Redesign Field Test
----------------------------------------------------------------------------------------------------------------
                                     Number of     Responses per   Total number      Hours per     Total burden
           Instrument               respondents     respondent     of responses      response          hours
----------------------------------------------------------------------------------------------------------------
Household Screening.............           8,110               1           8,110           0.083             673
Interview.......................           4,000               1           4,000           1.000           4,000
Screening Verification..........             246               1             246           0.067              17
Interview Verification..........             600               1             600           0.067              40
                                 -------------------------------------------------------------------------------
    Total.......................           8,110  ..............          12,596  ..............           4,730
----------------------------------------------------------------------------------------------------------------

    Written comments and recommendations concerning the proposed 
information collection should be sent by September 12, 2019 to the 
SAMHSA Desk Officer at the Office of Information and Regulatory 
Affairs, Office of Management and Budget (OMB). To ensure timely 
receipt of comments, and to avoid potential delays in OMB's receipt and 
processing of mail sent through the U.S. Postal Service, commenters are 
encouraged to submit their comments to OMB via email to: 
[email protected]. Although commenters are encouraged to send 
their comments via email, commenters may also fax their comments to: 
202-395-7285. Commenters may also mail them to: Office of Management 
and Budget, Office of Information and Regulatory Affairs, New Executive 
Office Building, Room 10102, Washington, DC 20503.

Summer King,
Statistician.
[FR Doc. 2019-17282 Filed 8-12-19; 8:45 am]
 BILLING CODE 4162-20-P